Mesa Laboratories Inc
MLAB
Industrial Instruments For Measurement, Display, and Control
Mkt Cap
$615.1MPE
648.86Debt
$171MCash
$28.22MEV
$757.9MFCF
$40.71MP/E Ratio
648.86Debt
$171MCash
$28.22MEV
$757.9MFCF
$40.71MCharts data: {"Earnings":[{"time":"2015-03-30","value":9583000},{"time":"2016-03-30","value":11169000},{"time":"2017-03-30","value":11183000},{"time":"2018-03-30","value":-2962000},{"time":"2019-03-30","value":7484000},{"time":"2020-03-30","value":1349000},{"time":"2021-03-30","value":3274000},{"time":"2022-03-30","value":1871000},{"time":"2023-03-30","value":930000}],"Sales":[{"time":"2015-03-30","value":71330000},{"time":"2016-03-30","value":84659000},{"time":"2017-03-30","value":93665000},{"time":"2018-03-30","value":96179000},{"time":"2019-03-30","value":103135000},{"time":"2020-03-30","value":117687000},{"time":"2021-03-30","value":133937000},{"time":"2022-03-30","value":184335000},{"time":"2023-03-30","value":219080000}],"Net Margins":[{"time":"2015-03-30","value":0.13434739941118745},{"time":"2016-03-30","value":0.13192926918579242},{"time":"2017-03-30","value":0.11939358351572092},{"time":"2018-03-30","value":-0.030796743571881596},{"time":"2019-03-30","value":0.07256508459785718},{"time":"2020-03-30","value":0.011462608444433114},{"time":"2021-03-30","value":0.024444328303605427},{"time":"2022-03-30","value":0.010149998643773564},{"time":"2023-03-30","value":0.004245024648530217}],"Assets":[{"time":"2015-03-30","value":117320000},{"time":"2016-03-30","value":160748000},{"time":"2017-03-30","value":171733000},{"time":"2018-03-30","value":164101000},{"time":"2019-03-30","value":156767000},{"time":"2020-03-30","value":420206000},{"time":"2021-03-30","value":601475000},{"time":"2022-03-30","value":707369000},{"time":"2023-03-30","value":661832000}],"Stockholders Equity":[{"time":"2015-03-30","value":73479000},{"time":"2016-03-30","value":84678000},{"time":"2017-03-30","value":97821000},{"time":"2018-03-30","value":99361000},{"time":"2019-03-30","value":111311000},{"time":"2020-03-30","value":220013000},{"time":"2021-03-30","value":406227000},{"time":"2022-03-30","value":393801000},{"time":"2023-03-30","value":393480000}],"ROE":[{"time":"2015-03-30","value":0.13041821472801754},{"time":"2016-03-30","value":0.1318996669737122},{"time":"2017-03-30","value":0.11432105580601302},{"time":"2018-03-30","value":-0.02981048902486891},{"time":"2019-03-30","value":0.06723504415556414},{"time":"2020-03-30","value":0.00613145586851686},{"time":"2021-03-30","value":0.008059533216649805},{"time":"2022-03-30","value":0.0047511306472050605},{"time":"2023-03-30","value":0.002363525465080817}],"ROA":[{"time":"2015-03-30","value":0.1352199113535629},{"time":"2016-03-30","value":0.10154403165202677},{"time":"2017-03-30","value":0.09499047940698643},{"time":"2018-03-30","value":0.01330278304215087},{"time":"2019-03-30","value":0.06616188355967774},{"time":"2020-03-30","value":0.021268139912328714},{"time":"2021-03-30","value":0.020546157363148927},{"time":"2022-03-30","value":0.006647167178657815},{"time":"2023-03-30","value":0.005016378778904616}]}
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
DCF
Discounted Cash Flow Valuation of Mesa Laboratories Inc
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $40.71M | $41.98M | $43.29M | $44.64M | $46.03M | $47.47M | $48.95M | $50.47M | $52.05M | $53.67M | $55.34M | $553.4M |
| DCF | $36.5M | $32.73M | $29.35M | $26.32M | $23.6M | $21.16M | $18.97M | $17.01M | $15.26M | $13.68M | $136.8M | |
| Value | $371.4M | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth -23%
Earnings Stability 26%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 03-2015 | 03-2016 | 03-2017 | 03-2018 | 03-2019 | 03-2020 | 03-2021 | 03-2022 | 03-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 13% | 13% | 12% | -3.1% | 7.3% | 1.1% | 2.4% | 1% | 0.42% | 0.45% |
| ROA | 14% | 10% | 9.5% | 1.3% | 6.6% | 2.1% | 2.1% | 0.66% | 0.5% | 0.027% |
| ROE | 13% | 13% | 11% | -3% | 6.7% | 0.61% | 0.81% | 0.48% | 0.24% | 0.24% |
What is the average Net Margin?
The average Net Margin over the past 5 years is +1.53%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is 0%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +2.22%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -0.63%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +0.98%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -0.07%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 03-2015 | 03-2016 | 03-2017 | 03-2018 | 03-2019 | 03-2020 | 03-2021 | 03-2022 | 03-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | 0.86 | 5.60 | 4.15 | 4.87 | 7.26 | 4.20 |
| Debt Equity | 0.40 | 0.57 | 0.58 | 469.26 | 0.23 | 0.64 | 0.36 | 0.43 | 0.43 | 0.42 |
| MIN | ||||||||||
| Graham Stability | - | - | - | -28% | 100% | 26% | 100% | 46% | 43% | -28% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is 4.20.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is 1.21.
What is the Graham’s Stability?
Graham’s Stability measure stands at -0.28.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 03-2016 | 03-2018 | 03-2020 | 03-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 15% | 18% | 23% | 19% | 2.1% |
| Net Income | -30% | - | -12% | -50% | -4.2% |
| Stockholders Equity | 25% | 32% | 21% | -0.082% | 1.6% |
| FCF | - | 1.3% | -2.2% | -33% | -12% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +17.9%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +2.1%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -4.2%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +31.69%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is +1.6%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +1.26%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -11.78%.